// OVERVIEW
SR One (formally SR One Capital Management, LP) is a biotechnology-focused venture capital firm that partners with founders and entrepreneurs to translate innovative science into medicines across therapeutic areas such as oncology, rare diseases, and neurodegeneration. Originally spun out from GSK in 2020, the firm operates with a transatlantic presence in Redwood City, CA and London, UK, and closed its second venture fund at $600M in 2023.
// RECENT MENTIONS
// SIGNALS
2 SIGNALS
01
funding·PitchBook News·MAY 1, 2026
“Avalyn — Raised $300M in US IPO; backed by SR One and Novo Nordisk”
02
mention·PitchBook News·APRIL 21, 2026
“Odyssey Therapeutics, Boston-based biotech backed by SR One. Filed for an IPO.”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.